Bosight Medical Secures Series C Funding to Advance Adaptive Optics Ophthalmic Devices

Jun 20, 2025 11:30 CST Updated 11:30

Robotrak Technologies

Ophthalmic Medical Device R&D Developer

Source: Eye Future

Reprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.

SIYU Annual Activity Review:The First Global Ophthalmology Conference | The First Global Orthopedics Conference | The First Global Cardiovascular Conference | The First Global Medical Aesthetics Technology Conference

Coming Soon:

July 17, 2025, The 2nd Global Medical Technology Conference

September 4-5, 2025, the 3rd Global Surgical Robotics Conference

At a time when the landscape of high-end ophthalmic equipment in China has yet to fully unfold, an optical technology originating from astronomical observation is being introduced into frontline medical diagnosis and treatment by a Chinese medical technology company.

Recently,Robotrak Technologies Co., Ltd.(Abbreviation: Robotrak Technologies)AnnouncementCompletedSeries C Financing, including Nanjing Xingu Investment, Ophthalmic Optics, and Taiyu Investment. The specific financing amount has not been disclosed.This round of financing will be used for product iteration, market expansion, and global layout in the field of ophthalmic diagnostic equipment.。

Robotrak Technologies was founded in 2017, with a core team that has an international background in ophthalmic imaging engineering.Long-term focus onOptical Engineering, Adaptive Optics, Eye Tracking and AI Algorithm Fusion Applied in Ophthalmic EquipmentDevelopment.

This round of financing continues the company's global commercialization process launched at the end of 2024. As early as a month ago,ARVO 2025 Annual MeetingDuring this period, Robotrak TechnologiesAdaptive Optics Fundus Imaging System "Stellaris®" Receives Over $8 Million in Intentional OrdersSingle, becoming one of the significant signals for the overseas expansion of high-end ophthalmic equipment made in China.

# The Revolutionary Crossover of Adaptive Optics

Originating from the field of astronomical observation, Adaptive Optics (AO) technology has long been regarded as the theoretical ceiling of high-resolution imaging due to its precise ability to correct minute wavefront distortions. However, its large system size and high integration costs have also kept it within the research domain in ophthalmology.

Robotrak Technologies has continuously invested 7 years in this field, successively overcoming several key technologies such as optical design, eye movement compensation, and image reconstruction, compressing the originally bulky experimental system into a clinically usable size.The device's volume has been reduced to 1/50 of its original size, and the manufacturing cost has been lowered to 1/20, achieving commercial implementation for the first time.。

This transformation not onlyImproved the resolution of fundus images to0.7μm, almost10 times that of traditional equipment，It also provides doctors with the possibility to observe individual cone cells, capillaries, and nerve fibers in the living retina, allowing fundus diseases to progress from "visible" to "measurable."

# Redefining the Diagnostic and Treatment Standards for Fundus Diseases

In the clinical application at Beijing Tongren Hospital, Capital Medical University, the "Stellaris®" system has achieved early photoreceptor cell loss detection in hereditary retinal diseases. Although this group of diseases has a relatively low incidence globally, they carry a high risk of blindness, and their early symptoms are difficult to capture with traditional equipment, often causing patients to miss the optimal intervention window.With high-resolution imaging, doctors are able to identify lesions in a timely manner before significant vision loss occurs, gaining a critical time window for early treatment.。

In addition,StellarVision® has achieved dynamic observation of retinal hemodynamics for the first time., allowing for a clear view of the blood cell flow within capillaries while also capturing vascular wall cell images, vessel wall thickness, blood flow velocity, and multiple other quantitative metrics. This has revolutionary significance for the early diagnosis of vascular conditions such as diabetic retinopathy.

"StellarVision®" SystemAchieving Sub-Micron In Vivo Imaging Through Engineered Adaptive Optics, showing potential in the ultra-early screening of hereditary retinal diseases, diabetic retinopathy, and others, building a new bridge between basic research and personalized diagnosis and treatment.

# Build a Multi-dimensional Product Matrix

Based on core technologies, Robotrak Technologies actively builds coverageDiagnosis, Treatment and PreventionThe multi-dimensional product matrix.

In addition to the high-resolution "Stellaris®" fundus imaging system, it was approved in 2024."Ranklight®" Intelligent Fundus Navigation Laser Equipment, becomingThe First Product in ChinaA Class III medical device integrating real-time ultra-wide-angle HD imaging, high-speed eye tracking, and AI-assisted treatment planning. The deviceBreakthrough Traditional Slit Lamp Microscope LimitationsDoctors can achieve digital and precise laser treatment through the screen, combined with 5G remote technology, to extend high-quality fundus treatment resources to grassroots levels.

"Ranklight®"Integrating image acquisition, diagnosis, planning, and treatment into a single window, doctors can directly complete operations on the screen, enhancing field control and operational precision. This system has also been categorized as an "intelligent assisted treatment product" and selected for the innovative tasks list of artificial intelligence medical devices led by the Ministry of Industry and Information Technology and the National Medical Products Administration.

Clinically,RankLight® and StarMirror® Enable Imaging-Target Linkage, improving the precision and closed-loop efficiency of the treatment.

In addition, for adolescent myopia prevention and control, Robotrak Technologies has also developedFunctional Contact Lens Product Line, in conjunction with imaging diagnostic equipment, forms a closed-loop for early screening, diagnosis, treatment, and intervention.

This full life-cycle eye health ecosystem layout reflects the company's transformation strategy from a single technology provider to a comprehensive solutions supplier, committed to meeting the diverse needs of different age groups.

# Dual Pathways to Breaking Barriers

Ophthalmic medical devices are at the starting point of structural reshaping. On the one hand, more than 40 million patients with fundus diseases and over 50% myopia rate among teenagers together constituteLarge yet underserved clinical needs; on the other hand, the core equipment market has long been dominated by a few international giants, with high-end diagnostic and treatment methods highly reliant on imported equipment,Lack of Original Research and Domestic Alternatives。

Against this backdrop, Robotrak Technologies has chosen to focus on technological originality as its core strategy.Avoiding "Homogeneous Competition" Pathway, directly targeting the unmet gaps in the industrial structure. Its commercialization strategy did not simply pursue market penetration, but ratherAdopt the "Research First" Model, prioritizing the deployment of products to top-tier research institutions and tertiary hospitals with influence and international clout, forming a positive cycle of technical validation and academic endorsement.

The successful installation of "StellarVision®" at the Visual Research Center of the University of Washington marks the international recognition of its adaptive optics system in the field of ophthalmic research. Through the dual deployment of "Research Edition + Clinical Edition," Robotrak Technologies has not only validated its technology but also paved the way for future service model expansion, personalized diagnosis and treatment support, and integration into digital platforms.

This technology-driven breakthrough has not only redefined the starting point for high-end ophthalmic devices produced in China but also provided the capital market with a new dimension for evaluation:To evaluate an innovative medical device company, it is not only about the number of products and registered certificates, but also about whether it can reshape the "standards" and become a builder of industry language.。

Welcome companies to actively participate in the conference organized by Siyu ↓

July 17, 2025, The 2nd Global Medical Technology Conference

September 4-5, 2025, The 3rd Global Surgical Robotics Conference

GOC2025

Award Review:29 Items! 2025 Global Ophthalmology Innovation Series Awards

Conference Review:Full Review of the First Global Ophthalmology Conference: The "Starry Sea" of Ophthalmic Innovation

Ophthalmology Solutions Case

Cataract Total Solution #SightMed

Comprehensive Vision Care Solutions #Johnson & Johnson

Glaucoma Comprehensive Solution #Haisi Gaidé

Ophthalmic Instruments Industry Research

Latest Industry Research | A Comprehensive Overview of the OCT Industry Landscape

A Brief Overview of the Development History of Fundus Cameras

An Overview of Intraocular Lenses

An Overview of Digital Therapeutics in Ophthalmology

An Overview of the Orthokeratology Lens Track